Pang Phillip 4
4 · Vir Biotechnology, Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4
Pang Phillip
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-01-02$1.57/sh+13,576$21,382→ 220,409 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-02$0.85/sh−18,833$16,102→ 0 totalExercise: $0.85Exp: 2027-03-09→ Common Stock (18,833 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-02$1.53/sh−47,591$72,814→ 0 totalExercise: $1.53Exp: 2028-04-27→ Common Stock (47,591 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-01-02$1.57/sh−13,576$21,382→ 0 totalExercise: $1.57Exp: 2028-07-19→ Common Stock (13,576 underlying) - Exercise/Conversion
Common Stock
2024-01-02$1.53/sh+47,591$72,814→ 268,000 total - Exercise/Conversion
Common Stock
2024-01-02$0.85/sh+18,833$16,102→ 206,833 total
Footnotes (3)
- [F1]1/4 of the shares subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.
- [F2]1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vested in 36 equal monthly installments thereafter.
- [F3]1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vested in 36 equal monthly installments thereafter.